On November 29, 2022, Cajal Neuroscience Inc. closed the transaction. The round of funding co-led by new investor The Column Group LLC, and Lux Capital Management, LLC. The transaction also involved participation from new investors Two Sigma Ventures, LP, Bristol-Myers Squibb Company, Alexandria Venture Investments, LLC, Evotec SE, Dolby Family Ventures, L.P, and other investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.52 EUR | -1.30% | -2.46% | -55.26% |
May. 06 | EVOTEC : Warburg Research reiterates its Buy rating | ZD |
May. 03 | EVOTEC : RBC reiterates its Buy rating | ZD |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
44.94 USD | +0.45% | +2.16% | 91.1B | ||
9.52 EUR | -1.30% | -2.46% | 1.82B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.26% | 1.82B | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- EVT Stock
- News Evotec SE
- Cajal Neuroscience Inc. announced that it has received $95.7 million in funding from The Column Group LLC, Lux Capital Management, LLC, Two Sigma Ventures, LP, Bristol-Myers Squibb Company, Alexandria Venture Investments, LLC, Dolby Family Ventures, L.P and other investors